Investment Thesis
Entera Bio is a pre-revenue biotech company with zero reported sales (-76.8% YoY) and substantial operating losses of $3.5M per quarter, generating negative operating and free cash flows of -$3.1M. With only $4.1M in cash and current burn rate, the company has approximately 1-2 quarters of runway remaining, creating an acute solvency risk absent immediate capital infusion or revenue generation.
Strengths
- Zero debt and clean balance sheet (Debt/Equity: 0.00x)
- Strong short-term liquidity (Current Ratio: 7.93x, Quick Ratio: 7.93x)
- Insider trading activity (10 Form 4 filings) suggests continued stakeholder engagement
Risks
- Zero/near-zero revenue with 76.8% YoY decline indicates failed commercialization or product launch
- Negative operating cash flow of $3.1M per quarter with only $4.1M cash = critical runway of 1-2 quarters
- Severe shareholder dilution evidenced by positive EPS despite negative net income, eroding per-share value
- Pre-revenue biotech with no visible path to profitability or product market fit
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue recognition and commercial product launch timeline
- Operating cash flow inflection toward positive territory
Financial Metrics
Revenue
0.0
Net Income
-3.5M
EPS (Diluted)
$0.07
Free Cash Flow
-3.1M
Total Assets
13.1M
Cash
4.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-32.8%
ROA
-26.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.93x
Quick Ratio
7.93x
Debt/Equity
0.00x
Debt/Assets
18.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:27:39.062085 |
Data as of: 2026-03-31 |
Powered by Claude AI